Table 6.

Adverse Effects of Medical Therapy for Thyroid Eye Disease

Drug (ref)	Frequency (%)	Severitya
		Minor (Grade 1)	Moderate (Grade 2)	Severe (Grade 3)	Life threatening (Grades 4–5)
IVGC68,72,74	≥10		Hyperglycemia
	5–9.9	GI symptoms		Infection
	1–4.9	Flushing	Hypertension depression Weight gain	Psychosis
	<1				Death, hepatic necrosis, myocardial infarction, stroke
OGC66,74	≥10	GI symptoms	Hyperglycemia, weight gain, Cushingoid facies		Not reported
	5–9.9		Hypertension	Infection
	1–4.9		Depression
MMF106	1–4.9			Infection, hepatitis
MMF+GC68	≥10	GI symptoms		Infection
	5–9.9
	1–4.9		Sleep disorder
RTX53,67,100	≥10		Infusion reaction (nonsevere)
	5–9.9	GI symptoms		Transient visual lossb
	1–4.9			Vasculitis
	<1				Infusion reaction (severe)
TEP89–91	≥10	GI symptoms, myalgias, alopecia, fatigue	Hyperglycemia	Hearing loss, inflammatory bowel disease aggravation
	5–9.9	Dry skin	Taste disturbance
	1–4.9				Cerebral hemorrhage
TCZ84,111,112	≥10	Fatigue	Hyperlipidemia, neutropenia	Infection
	5–9.9	Pruritus		Hepatitis
	1–4.9		Thrombocytopenia Transaminase elevation
	<1				Anaphylaxis Bowel perforationc

^a National Cancer Institute Common Terminology Criteria for Adverse Events (ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf). Grade 1: Mild, asymptomatic or mild symptoms, clinical or diagnostic observations only, intervention not indicated. Grade 2: Moderate; minimal, local, or noninvasive intervention indicated; limiting age-appropriate instrumental ADL. Grade 3: Severe or medically significant but not immediately life threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care ADL. Grade 4: Life-threatening consequences, urgent intervention indicated. Grade 5: Death related to adverse event.

^b Believed related to cytokine release syndrome.

^c Observed in other studies (not described in TED studies).

ADL, activities of daily living; GI, gastrointestinal; PML, progressive multifocal leukoencephalopathy.